Pro Bono Bio (PBB), the world leader in nano-physical medical devices, is proud to announce that it has been appointed as an official supplier to top English premiership rugby club, Saracens, for their breakthrough joint-care product, FLEXISEQ®.
This announcement is the culmination of nearly 6 months of collaboration between PBB and the Saracens medical staff who have been trialling FLEXISEQ among players of their elite squad, since the product hit the UK market in early December 2013.
FLEXISEQ, an injection-free biolubricant for joints, is a revolutionary new wellness product for the maintenance of joints that are either compromised by arthritic symptoms or those that are at higher risk of suffering wear and tear. The topically applied product delivers joint lubrication replacement therapy which coats cartilage surfaces to minimise friction and wear.
Saracens Joe Collins, Head of Medical, said “This is a fantastic product and one the medical team are proud and happy to have associated with the Club”.
One of the players who has benefited from FLEXISEQ is Saracens, England and British & Irish Lions centre, Brad Barritt, “FLEXISEQ has been a great product for me to use and has enabled me to train and compete at my best. FLEXISEQ offers me peace of mind in that it is drug-free and by lubricating my joints it protects them, shortens my recovery time and hopefully will prolong my career.”
John Mayo, CEO of PBB said, “As we have already proved in the arthritis field, FLEXISEQ is a game-changer and we expect the same outcome having entered the sports medicine and wellness sectors. Elite, high impact rugby is the ultimate sports test for joints. We are proud to have successfully proven FLEXISEQ in this testing environment with the Saracens medical team and wish each player and the Saracens team continued success”.
FLEXISEQ fits extremely well into the field of sports medicine where healthcare professionals are overloaded with joint injuries and are ever-vigilant for safer, drug-free ways to treat them. The physicality of rugby puts extraordinary stress and strain on players’ bodies and injuries are inevitable. These injuries can involve joint damage which can predispose a player to the early onset of further joint problems such as osteoarthritis. FLEXISEQ provides joint lubrication replacement therapy to those joints where their natural wear and tear-reducing properties may be compromised. The product is being used by Saracens as a drug-free solution to joint pain and stiffness as well as an additional step in players’ rehabilitation and after-care. Replacing painkillers (such as commonly used non-steroidal anti-inflammatory drugs) saves sportsmen and women from the well documented risks of side effects and slowing of the natural recovery and rehabilitation that can be caused by these painkillers.
Ascension Healthcare plc is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for the treatment of haemophilia and osteoarthritis. The Company has three products in clinical development for the treatment of haemophilia A and also a range of internationally marketed products for osteoarthritis sufferers. For more information please visit: www.ascension.co.uk/
For more information contact
Ascension Healthcare plc
Biresh Roy, Chief Executive Officer
[email protected] / +44 (0)20 7291 5400
Consilium Strategic Communications
(European Media and Investor Enquiries)
Lindsey Neville, Ashley Tapp
Tel: +44 (0)20 3709 5700 / [email protected]